Third, Fava concludes, excessive reliance on checklist criteria is likely to “impoverish the clinical process” and clinical ...

Abstract: Clinical research has demonstrated that exploring behavioral signal differences between depressed patients and non-depressed people using audiovisual technology is an effective approach for ...

OYE Therapeutics has been authorized to initiate clinical development of its OYE-101 caffeine injection after the U.S. FDA cleared its Investigational New Drug applications. OYE-101 is a novel ...

New sublingual delivery system designed to enhance bioavailability and speed of onset for major depressive and ...

Solvonis Therapeutics PLC (LSE:SVNS) chief scientific officer Professor David Nutt talked with Proactive's Stephen Gunnion ...

In a first, this week the U.S. Food and Drug Administration approved a brain stimulation device designed to treat depression at home. The approval of the first such device for home depression ...

Lipocine expects trial data to support a 505(b)(2) new drug application submission for LPCN 1154 in 2026.

Lipocine ( (LPCN)) has shared an announcement. On January 20, 2026, Lipocine announced it has completed enrollment and dosing of 90 patients in its Phase 3 clinical trial of LPCN 1154, an oral ...

Analysis and insights for driving a rapid transition to net-zero while building resilience to physical climate impacts ...

Share on Pinterest A recent review shows that exercise may be nearly as effective as therapy for depression. Image Credit: Oleg Breslavtsev/Getty Images A recently updated Cochrane review found that ...

A large review of studies suggests that exercise can ease depression about as effectively as psychological therapy. Compared with antidepressants, exercise showed similar benefits, though the evidence ...

Exercise may reduce symptoms of depression to a similar extent as psychological therapy, according to an updated Cochrane review. When compared with antidepressant medication, exercise also showed a ...